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Combined cell and gene-based therapeutic strategies offer potential in the treatment of
neurodegenerative and psychiatric conditions that have been associated with structural
brain disturbances. In the present investigation, we used a novel virus-free re-programming
method to generate induced pluripotent stem cells (iPSCs), and then subsequently
transformed these cells into neural cells which over-expressed brain derived neurotrophic
factor (BDNF). Importantly, the infusion of iPSC derived neural cells (as a cell replacement
and gene delivery tool) and BDNF (as a protective factor) inﬂuenced neuronal outcomes.
Speciﬁcally, intracerebroventricular transplantation of iPSC-derived neural progenitors that
over-expressed BDNF reversed the impact of immune (lipopolysaccharide) and chronic
stressor challenges upon subventricular zone adult neurogenesis, and the iPSC-derived
neural progenitor cells alone blunted the stressor-induced corticosterone response. More-
over, our ﬁndings indicate that mature dopamine producing neurons can be generated
using iPSC procedures and appear to be viable when infused in vivo.Taken together, these
data could have important implications for using gene-plus-cell replacement methods to
modulate stressor related pathology.
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INTRODUCTION
Just as is the case with neurodegenerative diseases, psychiatric
conditions such as major depression, schizophrenia and post-
traumatic stress disorder have been associated with structural
brain changes, including reductions of adult neurogenesis, den-
dritic arborization and hippocampal volume (Andreasen et al.,
2011; Kroes et al., 2011; Lee et al., 2013; Na et al., 2014). More-
over, it is well established that psychological and immuno-
logical stressors can promote structural brain changes, includ-
ing altered neurogenesis and dendritic branching, along with
marked hormonal variations (e.g., glucocorticoids; Anisman
et al., 2008; Hayley, 2011). Accumulating evidence suggests
that the deﬁciencies in growth factors, most notably brain
derived neurotrophic factor (BDNF), likely contribute to the
aberrant structural changes (Hasbi et al., 2009; Hayley and
Litteljohn, 2013; Vithlani et al., 2013). Indeed, this growth
factor is a critical mediator of neuroplasticity and neuropro-
tection, and has been implicated in many neurodegenera-
tive and psychiatric disorders (Nagahara and Tuszynski, 2011;
Autry and Monteggia, 2012). In fact, virtually all effective
anti-depressant treatments inﬂuence BDNF and enhance neuro-
plasticity (Saarelainen et al., 2003; Schmidt and Duman, 2007,
2010). Given that BDNF does not cross the blood–brain bar-
rier and can have deleterious systemic effects (Makar et al., 2009;
Pilakka-Kanthikeel et al., 2013), ﬁnding novel means of deliv-
ering BDNF to the brain over long time periods is of great
importance.
One exciting currently evolving approach to the potential
delivery of trophic factors and the engagement of “repair”
mechanisms within the brain involves the use of stem cell
based technologies. In particular, the transcription factors, Oct4
(octamer-binding transcription factor 4), Sox2 [SRY (sex deter-
mining region Y)-box 2], Klf4 (Krüppel-like factor 4), and
c-Myc (cellular myelocytomatosis oncogene), are capable of
re-programming adult ﬁbroblasts into induced pluripotent stem
cells (iPSCs), which can be further differentiated into targeted
functional types of cells, including neurons (Breton et al., 2013;
Faiz and Nagy, 2013). Importantly, iPSC derived cells have been
posited to have clinical potential as a cell replacement strategy or
means of inducing neuroplasticity in neurodegenerative disorders,
such as Parkinson’s disease, Alzheimer’s disease and spinal cord
injury, and possibly even neuropsychiatric illnesses (Vaccarino
et al., 2011; Yagi et al., 2012; Faiz and Nagy, 2013).
Genetic- (e.g., gene targeting) and- cellular restoration-based
therapies (e.g., iPSCs) have been considered as totally indepen-
dent, and even mutually exclusive, approaches to treatment, even
though they have obvious commonalities (Müller et al., 2006).
With regard to the brain, both approaches seek to modify neu-
ral circuitry or protein levels either by (1) altering existing gene
expression within brain cells, or (2) promoting the integra-
tion of novel cells into existing/damaged neural circuits. In the
present investigation we combined these two strategies by over-
expressing BDNF in iPSC-derived immature neural cells and
sought to determine whether central infusion of these cells would
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modify the impact of stressor exposure. We chose a compound
stressor comprising lipopolysaccharide (LPS) plus a chronic psy-
chological stressor regimen, which previously elicited robust
hypothalamic–pituitary–adrenal (HPA), behavioral and neuro-
chemical changes (Gibb et al., 2011). Our current methods also
utilized a non-viral method for the reprogramming of ﬁbrob-
lasts into iPSCs, thereby minimizing the potential for tumor
formation (as was previously reported with retroviral methods;
Wernig et al., 2008). Finally, we also tested the ability of our
procedures to create mature dopamine producing neurons and
whether these cells would survive, at least for the short term,
when infused in vivo. Our “enhanced gene-cell approach” per-
mits the exploration of potential additive or synergistic effects
of iPSC-derived cells together with gene-directed expression of
BDNF.
MATERIALS AND METHODS
Figure 1 depicts the timing of the experiments, which are
described in detail in the ensuing sections.
VECTOR CONSTRUCTION
We utilized a non-viral vector, termed pCAG2LMKOSimO (vec-
tor 20866, Addgene), for reprogramming somatic ﬁbroblasts into
iPSCs (Kaji et al., 2009). This vector takes advantage of pro-
ducing virus-free, factor-removable iPSCs by applying a single
plasmid with a 2A-peptide-linked reprogramming cassette, c-
Myc-Klf4-Oct4-Sox2-(MKOS)-IRES-mOrange, ﬂanked by loxP
sites. These reprogramming genes are transcribing from the uni-
versally expressed synthetic CAG enhancer/promoter (Niwa et al.,
1991; Szymczak et al., 2004). Contained in this vector are the cod-
ing sequences of four transcription factor genes, namely c-Myc,
Klf4, Oct4, and Sox2, which together comprise the reprogram-
ming cassette; vector 20866 also contains the mOrange marker for
gene expression.
The full sequence of 750 bp cDNA for BDNF from mus mus-
culus (GenBank BC034862) was constructed using polymerase
Table 1 | Brain derived neurotrophic factor primers for cloning PCR
product or sequencing complete cDNA construct.
Genes Primers
Full cDNA BDNF Forward accaggtgaCTCGAGgaagagtgatgaccatcc
Reverse cataaatccactaGTCGACtcttccccttttaatgg
Sequencing BDNF BDNF-r1 CAAGTTGCCTTGTCCGTG
BDNF-r2 CCTGGGCCCATTCACGCTCTCCAGAG
BDNF-f1 CATCCTTTTCCTTACTATGGTTATTTC
BDNF-f2 CAGTCAAGTGCCTTTGGAG
BDNF-f3 CAAGTGTAATCCCATGGGTTAC
chain reaction (PCR; Table 1 for the Primer Lists) and cloned
into the pZsYellow1-N1 Vector (Clontech 632445) at the ligation
sites of XhoI and SalI. cDNA BDNF expression was driven by the
human cytomegalovirus (CMV) enhancer/promoter. The com-
plete mouse cDNA for BDNF was veriﬁed by Sanger Sequencing,
usingApplied Biosystem’s 3730xlDNAAnalyzer technology at The
McGill University Innovation Centre (Table 1 for the Primers).
Full cDNA BDNF was transfected into adult mouse primary
hippocampal or pituitary cells, as well as adult rat primary hip-
pocampal cells for veriﬁcation of gene expression (Figure 2).
Primary hippocampal and pituitary cell cultures were prepared
from adult (aged 2 months; CD1) mice.
TISSUE PREPARATION AND CELL CULTURE
Fibroblasts were isolated from tail-tips of adult (aged 2 months;
CD1) mice and collected in Dulbecco’s Modiﬁed Eagle Medium:
Nutrient Mixture F-12 (DMEM/F12, Invitrogen 10565-018).
Culture vessels were coated with poly-D-lysine (ﬁnal coating con-
centrations from 1μg/cm2 of surface area,MilliporeA-003-E) and
laminin (ﬁnal coating concentrations from 1 μg/cm2 of surface
area, Invitrogen 23017-015).
FIGURE 1 | Outline of the specific experiments conducted. Adult mouse
ﬁbroblast cells were reprogrammed into induced pluripotent cells (iPSCs)
using the vector 20866 containing the c-Myc, Klf4, Oct4, and Sox2 genes.
iPSCs were further sequentially transformed into immature neural progenitor
cells (after 35 days in culture) and mature dopamine neuronal cells (after
50 days in culture). In Experiment 1, iPSC-derived neural progenitor cells
alone or with the additional cDNA BDNF were infused in order to determine
their ability to reverse the impact of psychological and immunological
[lipopolysaccharide (LPS)] stressor exposure. Experiment 2 involved the
generation of iPSC-derived mature DA neurons (with and without cDNA
BDNF transfection) and assessment of their survival following central
infusion.
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FIGURE 2 |Verified full-length gene sequence of BDNF cDNA. A 750 bp
PCR product for cDNA BDNF was present on a 1% agarose gel (A). The
full-length cDNA BDNF was then cloned into a pZsYellow1-N1 Vector and
veriﬁed by sequencing (B), as well by immunoﬂuorescent detection
(anti-BDNF antibody from Abcam ab620; 1:150) in hippocampal (C) and
pituitary gland (D) primary cell cultures of adult CD1 mice.
Tissues were placed on a plate with 4 mL of the Hibernate®-E
Medium without Ca2+ (BrainBits LLC, HE-Ca) or DMEM/F12.
Pieces of tissue were then enzymatically digested using 2 mg/mL
of ﬁlter-sterilized papain (Worthington, Cat. no. LS003119) at
37◦C for 45 min. Subsequently, these were removed and spun
down and the supernatant re-suspended in 5 mL of complete
Hibernate®-E medium (BrainBits LLC) or knockout DMEM
(Invitrogen 10829-018). The tubes were further centrifuged for
4 min at 200 × g, after which supernatants were removed and cell
pellets re-suspended in 41.5 mL DMEM/F-12 (Invitrogen 10565-
018). A total of 50 mL of the medium was prepared by adding
a further 7.5 mL knockoutTM serum replacement (Invitrogen
10828-028), 0.5 mL L-glutamine (Invitrogen 25030-081), 0.5 mL
MEM Non-Essential Amino Acids Solution (NEAA; Invitrogen
11140-050), 50 μl of 10 μg/mL (ﬁnal 10 ng/mL) bFGF (Fibroblast
growth factors, Invtrogen 13256-029) and 91 μl (ﬁnal 0.1 mM)
β-mercaptoethanol (Invitrogen 21985-023). Cells were incubated
at 37◦C in a humidiﬁed atmosphere of 5% CO2 in ambient air,
and were freshly fed every third day with the appropriate medium.
REPROGRAMMING GENES AND INDUCTION OF PLURIPOTENCY
Once the aforementioned cells were cultured to 90% conﬂu-
ence, we transfected the vector 20866 and/or cDNA BDNF using
lipofectamine® 2000 Transfection Reagent (Invtrogen 11668-027),
according to the manufacturer’s instructions. Cells with/without
vector 20866 and/or BDNF cDNA were continually cultured with
fresh media. The cluster appearance of stem-cell-like colonies
expressing the mOrange-positive marker were distinguished at
Days 5–6 following transfection. The iPSCs were conﬁrmed
by means of positive alkaline phosphatase live stain (Invitro-
gen A14353), as well as an expression of stem cell stage-speciﬁc
antigens: SSEA-1, SSEA-3, Oct-4, and TRA-1-81 (Millipore
SCR002). The iPSCs with the mOrange-positive marker were
further recognized during Days 17–20 by live staining with TRA-
1-81, and then these were transported to cultures containing
a Neural Induction Medium in newly coated-plates or wells
comprising a 0.1% gelatin attachment factor solution (Invitrogen
S-006-100).
The cDNA transfection day was denoted as Day 0, and from
Days 1 to 14 the medium was changed and replaced with complete
N2B27 Medium (Invitrogen 11330-057, plus N-2 Supplement
17502-048, B-27® Supplement 17504-044, knockoutTM serum
replacement, L-glutamine, NEAA, β-mercaptoethanol), supple-
mented with a CHALP cocktail (containing MEK, TGF-b and
GSK3β inhibitors, along with human leukemia inhibitory factor)
which signiﬁcantly improved reprogramming efﬁciency (Yu et al.,
2011). During Days 15–20, the medium was changed to Essential
8TM Medium (Prototype), and was replaced every other day.
NEURAL PROGENITOR CELL INDUCTION
DuringDays 21–28, the undifferentiated iPSCs formedneural pro-
genitor cells following culture in the Neural Induction Medium.
Thismediumconsisted of 50mLNeurobasal®mediumwith bFGF,
heparin solution (Sigma H3149, 50 μl of 2-mg/mL), N-2 sup-
plement, glutaMAXTM-I supplement, NEAA, knockoutTM serum
replacement, and β-mercaptoethanol. The medium was changed
every other day.
MATURE DOPAMINE NEURONAL DIFFERENTIATION
To direct the neural progenitor cells to differentiate into dopamine
neural progenitors, cultures were fed every other day (Days 29–
35) with Dopamine Neuronal Progenitor Medium, containing
100 ng/mL FGF-8b (Invtrogen PHG0271) and 200 ng/mL sonic
hedgehog (SHH, R&D systems 1314-SH-025), as well as Neu-
robasal® medium, heparin solution, N-2 supplement without
vitamin A (Invtrogen 12587-010), and NEAA.
Subsequently, from Days 36 to 50 the dopamine neural pro-
genitor cells were further differentiated into mature dopamine
neurons by culturing in the Dopamine Neuronal Differentiation
Medium every other day. This medium comprises: recombinant
human BDNF (Invtrogen PHC7074, 50 μl of 25-μg/mL); recom-
binant human GDNF (Invtrogen PHC7045, 50 μl of 20-μg/mL);
ascorbic acid (SigmaA4403, 50 μl of 200 mM); dcAMP (Dibutyryl
cyclic-AMP; Sigma D0627, 50 μl of 1-mM) in 50 ml Neurobasal®
medium containing heparin; N-2 supplement without vitamin A
(Invitrogen 12587-010); and NEAA.
STEREOTAXIC INFUSION OF iPSC-DERIVED CELLS
12-month old male CD1 mice were used as experimental animals
for intracerebroventricular infusion.All procedureswere approved
by the Carleton University Committee for Animal Care and were
conducted in adherence to guidelines set out by the Canadian
Council for the Use and Care of Animals in Research. Brieﬂy, mice
were anesthetized with oxygen-enriched isoﬂurane, and placed in
a stereotaxic apparatus. All cannulae were implanted according to
the following stereotaxic coordinates: 0.14mmanterior to bregma,
0.75 mm lateral from the mid-sagittal suture, and 2.35 mm ventral
from a ﬂat skull surface. Animals were given 1 week to convalesce
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before experimentation. Intracerebroventricular infusion volume
was 4 μL (5 × 105) of the reprogrammed neural cells. Infu-
sions were delivered through polyethylene tubing connected to a
microliter syringe (Hamilton; Reno, NV, USA) and syringe pump
(Harvard Apparatus Pico Plus; Holliston, MA, USA). All infu-
sions were delivered at a rate of 0.4 μL/min, for a total of 10 min,
followed by a 5-min pause to ensure proper delivery. Infusions
were conducted between 08.30 and 14.00 h to avoid variabil-
ity attributed to diurnal variations. Furthermore, animals were
unrestrained during the infusion process to minimize stress.
CENTRAL INFUSION AND STRESSOR PROCEDURES
Experiment 1
For this study, mice were infused with LPS (2 μg dissolved in 4 μL
saline) or saline. At 24 h following the intracerebroventricular
infusion, a 3-week stressor regimen began, wherein mice received
a different stressor twice daily (as described in the upcoming
section). At the end of the ﬁrst week of stressor exposure regimen
and following the LPS/saline infusion, mice received a second sin-
gle intracerebroventricular infusion of either: (1) HBSS (vehicle),
(2) reprogrammed neural progenitors (iPSCs cultured for 35 days
in differentiation medium) alone, or (3) reprogrammed neural
progenitors plus complete cDNA BDNF. As well, a separate group
of HBSS infused animals did not receive any LPS or stressor treat-
ment. All animals were sacriﬁced 2 weeks following the second
infusion (i.e., at the end of the 3 weeks of stress).
The stressor exposure occurred twice daily (morning and after-
noon) and lasted for 3 weeks. The chronic stressor regimen
included the following stressors: restraint in semicircular Plexiglas
tubes (4 × 12 cm) with tails taped to prevent mice from turn-
ing (15 min); restraint in tight-ﬁtting triangular bags with a
nose-hole for breathing (15 min); exposure to social stressors
(interactions but not ﬁghting) by placing mice in a large cage
(40 cm × 25 cm × 15 cm) divided into separate quadrants with
three non-experimental mice (60 min); tail hanging (30 s); place-
ment in an empty cage without sawdust or nesting (60 min); lights
on during dark phase; intermittent background noise in an iso-
lated chamber (30 cm × 14 cm × 15 cm, 40 dB, 10 min); and
30◦ cage tilt (60 min). Following the ﬁrst (morning) daily stres-
sor, mice were returned to their home-cage until application of
the second (afternoon) stressor. Due to the nature of the stressor
paradigm, animals that received the chronic stressor regimen were
housed in holding rooms separate from, but otherwise identical
to, their non-stressed counterparts.
Experiment 2
Compared to immature neural progenitor cells, mature neu-
rons have a greatly reduced capacity for plasticity. There is
therefore a concern that the transformed mature dopaminer-
gic neurons might not survive after being transplanted into
the complex microenvironment of the brain. To examine this
possibility, iPSC-derived mature dopaminergic neurons, either
alone or additionally transfected with BDNF, were transplanted
into adult mouse lateral ventricles and infusion of the medium,
HBSS, served as the experimental control. Twenty-four hours
after cell transplantation (or vehicle infusion), cortical and hip-
pocampal brain regions were collected. These regions were
of interest given their close proximity to the infusion site,
along with their importance in mediating responses to stres-
sors. As it was previously reported that neural stem cells injected
into the striatum of tumor bearing rats migrated at a rate
of ∼175 μm/min (Kim et al., 2010), 24-h should be sufﬁ-
cient time for some degree of migration of the iPSC-derived
neurons.
For this study, (see Figure 1), mice did not receive any LPS or
stressor treatments. However, animals did get a single intracere-
broventricular infusion of either HBSS (control) or iPSC-derived
mature dopaminergic neurons (cultured for 50 days in differentia-
tionmedium), either alone or additionally transfectedwith BDNF.
Twenty-four hours after cell transplantation (or vehicle infusion),
cortical and hippocampal brain regions were collected in order to
ascertain whether the mature neurons survived in vivo.
QUANTITATIVE REAL-TIME PCR (qRT-PCR)
Total RNA was isolated using a GeneJET RNA Puriﬁcation kit
(Thermo scientiﬁc K0732) and then quantitative real-time PCR
(qRT-PCR) was carried out using a LightCycler® 480 RNA Mas-
ter Hydrolysis Probes kit (Roche 04991885001) according to the
manufacturer’s instructions. The TaqMan-gene-speciﬁc primers
were designed using Integrated DNA Technologies’ PrimeTime
qPCR Assay web application. TaqMan-gene-speciﬁc primers were
designed using an Integrated DNA Technologies proprietary soft-
ware program. All experiments were normalized for PCR sample
loading and reaction, and data represent one of three independent
experiments for ct (threshold cycle) plots. All gene expression val-
ues were normalized to total levels of the control housekeeping
gene, GAPDH, whose primers are presented in Table 1.
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
Cell samples were homogenized by ultrasonic disruption in
a 500 μl solution containing 0.1 mM NaEDTA, 0.3 M
monochloroacetic acid, 1% methanol in high performance liquid
chromatography (HPLC) grade water, with DHBA as an inter-
nal standard. The level of protein was determined with Pierce
BCA Protein Assay Kit (Thermo Scientiﬁc 23225). Homogenated
sampleswere centrifugated at 10000 rpmat 4ºC and50μl of super-
natant was injected, at a ﬂow rate of 1 ml/min, into the HPLC
system (Agilent 1100) with electrochemical detector (DECADE
SDC) and Eclipse XDB-C-8, 4.6-150 mm column. The mobile
phase consisted of 90 mM sodium dehydrogenate Phosphate,
1.1 mM 1-octane sulfuric acid, 50 mM EDTA (1 ml/2l of 100 mM
solution), and acetonitrile 10%, citric acid 50 mM, potassium
chloride 5 mM, and HPLC-grade water.
IMMUNOHISTOCHEMISTRY
For the assessment of in vitro stem cell markers, alkaline phos-
phatase live stain (Invtrogen, A14353) and Embryonic Stem (ES)
Marker Sample Kits (Millipore, SCR002) were applied. The latter
kit contains monoclonal antibodies for the detection of the cell-
surface stage-speciﬁc embryonic antigens (SSEA-1, SSEA-3, and
SSEA-4), as well as expression of TRA-1-60, TRA-1-81 antigens
and Oct-4. Neuronal cells were detected using immature neuronal
cell marker anti-DCX antibody (Invitrogen 48-1200), the mature
neuronal cell marker anti-MAP2 antibody (Abcam ab32454), the
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dopamine neuronal cell marker tyrosine hydroxylase (TH) anti-
body (ImmunoStar 22941). Brieﬂy, the primary antibodies were
diluted at 1:25 ratio in blocking solution (1× PBS/4% normal
goat serum/0.3% TritonTM X-100), and then incubated for 1 h at
room temperature following three washes with 1× Rinse Buffer.
Further, samples were incubated with ﬂuorescein isothiocyanate
(FITC)-labeled secondary antibodies for 1 h at room temperature.
Fluorescence images were visualized with an Olympus 1×2-UCB
series microscope and MediaCybernetics imaging software. Living
cell culture samples were assessed using a Zeiss Axiovert 40 CFL
microscope and Lumenera Inﬁnity software.
For assessment of adult neurogenesis, mice were sacriﬁced
by perfusion with saline followed by 4% paraformaldehyde
(PFA). Brains were post-ﬁxed in a solution of 30% sucrose in
4% PFA and were then ﬂash-frozen and cryostat sliced into
20-μm coronal sections containing the hippocampus and sub-
ventricular zone (SVZ). The hippocampal levels collected were
operationally deﬁned as early/rostral (bregma −1.22 to −1.82),
middle (bregma −1.82 to −2.46) and late/caudal (bregma −2.46
to −2.92), as we have previously reported (Seguin et al., 2009). The
SVZ levels were collected between bregma levels 0.26 to −0.10. All
tissue was immersed in heated tri-sodium citrate buffer (pH 8.5)
for antigen retrieval following preliminary washes with phosphate
buffered saline (PBS). Subsequently, tissue was blocked for 1 h
with 0.1 M tris-buffered saline containing 0.1 M PBS containing
0.1% sodium azide, 0.3% triton-X, and 2% bovine serum albu-
min (BSA). Sections were incubated with primary antibody for
doublecortin (DCX; Life Technologies 48-1200, 1:500) overnight
at 4ºC. Thereafter, sections were further incubated for 2 h at room
temperature with biotin anti-rabbit (Jackson ImmunoResearch
Laboratories; 1:1000). Primary and secondary antibodies were
diluted in 0.01 mol/l PBS (pH 7.3) containing 2% BSA with 0.3%
Triton X-100 and 0.01 sodium azide. Sections were further incu-
bated in horseradish peroxidase-conjugated streptavidin tertiary
antibody (1:1000; Jackson ImmunoResearch) at room tempera-
ture for 2 h. Antibodies were then visualized by incubation with
DAB (Sigma-Aldrich) for 10 min on a shaker table.
All quantitative analyses were performed in a blinded fash-
ion with the total number of bilaterally labeled DCX-positive
cells counted within the rostral, middle and caudal portions
of the dentate gyrus or between the SVZ bregma levels 0.26
to −0.10, as mentioned above. Using a 20× magniﬁcation,
the number of immuno-positive cells per section was manu-
ally counted for each of the three hippocampal levels, as well
as the overall total number of DCX+ cells within the sampled
SVZ region. Five different slides (with four sections/slide) for
each animal were quantiﬁed and the average number of DCX+
neurons determined for each animal and treatment comparisons
made.
WESTERN BLOT
Brieﬂy, cells or tissues were lysed and sonicated for 2 s and
protein concentrations were measured by a standard BCA assay
(Pierce). All samples were heated in Laemmli buffer and 15 μg
of total protein subsequently loaded on a 12.5% SDS-PAGE
gel. Blots were then probed with a rabbit polyclonal antibody
(Invitrogen 48-1200) against the immature neuronal cell marker,
DCX. Secondary antibodies that were HRP conjugated were then
applied and proteins visualized by ECL treatment and subse-
quent exposure to Kodak ﬁlm. For loading controls, all lanes
were loaded with beta actin antibody (abcam, ab8227) at 1/5000
dilution.
CORTICOSTERONE ANALYSES
Trunk blood was collected in tubes containing 10 μg EDTA, cen-
trifuged at 3600 rpm for 8 min, and 50 μL of plasma was then
collected for determination of corticosterone levels. Plasma was
immediately frozen at –80ºC until analyses. Corticosterone levels
were measured using a commercial radioimmunoassay kit (ICN
Biomedicals, CA, USA, Cat .no 07120002). Inter-assay variabil-
ity was avoided by assaying all samples (in duplicate) within a
single run.
STATISTICAL ANALYSES
A StatView (SAS Institute, version 6.0) statistical software package
was used for all computations. Behavioral, corticoid and immuno-
histochemical measures were analyzed for statistical signiﬁcance
using an appropriate analysis of variance (ANOVA),wherein treat-
ment infusion and stressor/LPS exposure vs. no stress were treated
as independent variables. Any signiﬁcant ﬁndings were followed
up using Bonferonni analyses.
RESULTS
OUTLINE OF EXPERIMENTS
The outline of the speciﬁc experiments conducted is presented
in Figure 1. Brieﬂy, these comprised studies in which (1) iPSCs
derived from re-programmed mouse tail-tip ﬁbroblasts were dif-
ferentiated into neural progenitor cells (that expressed DCX)
and infused into adult mouse lateral cerebral ventricles. After
a 3-week stressor challenge that comprised a combined sin-
gle LPS infusion followed by chronic psychogenic/neurogenic
stressor exposure, we assessed whether the transplanted cells
provided protection against stressor-induced changes in adult
neurogenesis and plasma corticosterone (Experiment 1) and (2)
iPSC-derived neural progenitors were further differentiated in
vitro into mature neurons (that expressed TH and MAP2 and
produced dopamine), and the in vivo survival of these cells
was assessed 24-h after intracerebroventricular transplantation
(Experiment 2).
VERIFICATION OF BDNF cDNA
Polymerase chain reaction product for full-length BDNF cDNA
was cloned into a pZsYellow1-N1 Vector, and veriﬁed by sequenc-
ing (Figures 2A,B). Its gene expression in vitro was determined by
immunoﬂuorescent detection using anti-BDNF antibody in hip-
pocampal (Figure 2C) and pituitary gland (Figure 2D) primary
cell cultures from adult CD1 mice.
VIRUS-FREE IN VITRO REPROGRAMMING OF MATURE FIBROBLAST
CELLS INTO iPSCs
We ﬁrst sought to optimize existing in vitro reprogramming meth-
ods established by Kaji et al. (2009). As mentioned in the methods,
adult mouse tail-tip ﬁbroblast cell cultures (from 2-month old
mice) were transfected with the non-viral vector 20866 containing
the four reprogramming transcription factors: Oct4, Sox2, Klf4,
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FIGURE 3 | In vitro iPSCs and neural progenitor cells produced from
adult mouse fibroblasts (see Materials and Methods). The panels show
that control (absence of the 20866 vector) tail cells still retain their
original shape on Day 47 after culturing (A). The presence of the
mOrange marker suggests that the ﬁbroblasts have successfully
integrated the 20866 plasmid (B). The iPSCs were further characterized by
an alkaline phosphatase live stain (C), as well as staining of the three
cell-surface stage-speciﬁc embryonic antigens: SSEA-1 to -4 (D–F),
TRA-1-60 (G), TRA-1-81 (H), and Oct-4 (I). By Day 18, iPSCs began
displaying projections (J) and further differentiation was clearly evident by
Days 20, 23, and 28 (K–M), respectively. By the later time point (M), the
cells had morphology consistent with that of neural progenitor cells and
displayed a robust induction of the immature neuronal marker,
doublecortin (N).
and c-Myc. The iPSC identity was established by the expression of
the ﬂuorescent vector marker, mOrange (Figure 3B), and further
veriﬁed using a numbers of markers – alkaline phosphatase live
stain (Figure 3C), as well as the cell-surface, SSEA-1 (Figure 3D),
SSEA-3 (Figure 3E), SSEA-4 (Figure 3F), TRA-1-60 (Figure 3G,
tumor rejection antigen 1-60), TRA-1-81 (Figure 3H), and Oct-
4 (Figure 3I). Thus, it appeared that successful reprogramming
occurred. Furthermore, the colonies were picked between Days
17–20, and seeded on gelatin-coated plates (Attachment Fac-
tor is sterile 1× solution containing 0.1% gelatin, Invitrogen
S-006-100).
EXPERIMENT 1: GENERATION OF NEURAL PROGENITOR CELLS FROM
iPSCs
Upon successfully demonstrating the ability of our non-viral
reprogramming system to generate pluripotency in vitro, our next
step was to produce cells of a neuronal phenotype. In particular,
we were initially most interested in generating neural progeni-
tor cells, given their relatively high degree of plasticity. Using
a speciﬁc neural induction medium, iPSCs were differentiated
into neural progenitor cells between Days 20 and 35. The neu-
ral morphology of these cells was quite apparent, with clear
soma and distinct neural processes being progressively evident
over time (Figures 3A–M). Moreover, the immature neuronal
marker, DCX, was clearly up-regulated in these cells, indicat-
ing that these newly generated neuronal precursors are no more
than 3 weeks of age and have not yet reached a mature stage
(Figures 3A–N).
iPSC-DERIVED NEURAL PROGENITOR CELLS BLUNTED THE IN VIVO
EFFECTS OF LPS+ STRESS
A single factor ANOVA indicated that the treatments were
associated with signiﬁcant plasma corticosterone changes,
F(3,16) = 9.00; p< 0.001 (Figure 4A). Follow-up Bonferonni cor-
rected tests conﬁrmed that the LPS-stressor challenge provoked a
robust and signiﬁcant rise of corticosterone (p < 0.05) relative to
non-stressed mice. As shown in Figure 4A, mice that were trans-
planted with the neural progenitors, regardless of whether the
cells had been further transfected with BDNF, displayed a signif-
icant attenuation of LPS + stressor-induced corticosterone levels
(p< 0.05), relative to animals that only received the LPS + stressor
treatment. Yet, all three LPS + stressor treatment group (regard-
less of iPSC infusion) still had corticosterone levels that exceeded
that of the non-stressed controls (p < 0.05).
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FIGURE 4 | As shown in the bar graph on the left (A), the single icv
LPS infusion (2 μg) plus a 3-week twice-daily different stressor
challenge (LPS + stress) increased plasma corticosterone, relative to
vehicle treatment (Veh). Icv infusion of either the iPSC-derived neural
progenitor cells alone (LPS + stress + iPSC) or in combination with the
cDNA BDNF (LPS + stress + iPSC + BDNF) attenuated the plasma
corticosterone rise induced by the LPS + stress treatment. The
photomicrograph on the right (B) displays doublecortin (DCX)
immunoreactivity in the subventricular zone (SVZ) in response to vehicle (a),
LPS + stressor exposure (b), LPS + stressor exposure + iPSC-derived
neural progenitor cells (c), or LPS + stressor exposure + iPSC-derived
neural progenitors + BDNF cDNA (d). As quantiﬁed in the bottom bar
graph, the LPS + stressor exposure alone or in combination with the
iPSC-derived neural progenitor cells signiﬁcantly reduced the number of
DCX+ cells within the SVZ (p < 0.05). However, infusion of the iPSC
derived neural progenitor cells that were transfected with cDNA BDNF
completely prevented this DCX reduction. *p < 0.05 relative to Veh
treatment, o p < 0.05 relative to LPS + stress treatment.
No signiﬁcant differences were observed between the treatment
groups for the number of DCXpositive neuronswithin the dentate
gyrus regionof the hippocampus. Indeed, the iPSCderived cellular
infusions did not signiﬁcantly affect the number of DCX+ neu-
rons at either of the three different hippocampal levels sampled
(data not shown). However, signiﬁcant between-groups differ-
ences were evident within the SVZ, F(3,18) = 5.02, p < 0.05.
As shown in Figure 4B and conﬁrmed by follow up compar-
isons, LPS + stressor exposure provoked a signiﬁcant reduction
in the total number of DCX-expressing neurons within the sam-
pled SVZ (p < 0.05), and this effect was totally prevented by
co-treatment with the iPSC-derived neural progenitors that also
expressed BDNF. Interestingly, infusion of iPSC-derived neural
progenitors that did not co-express BDNF had no signiﬁcant effect
on DCX cells (Figure 4B), suggesting the importance of this
trophic factor in modulating SVZ neurogenesis. It is likely that
the SVZ and not the hippocampal neurons were affected given
their proximity to the lateral ventricular site of infusion. Impor-
tantly, previous studies have indicated that SVZ neurons may act
as a reservoir of cells that are especially sensitive to stressful events,
often migrating toward sites of brain injury (e.g., following cere-
brovascular stroke) and infection (Goings et al., 2008; Ahlenius
et al., 2012).
EXPERIMENT 2: GENERATION OF MATURE DOPAMINERGIC NEURONS
IN CULTURE
Ensuing experiments involved mature dopaminergic neurons dif-
ferentiated from neural progenitors generated from our iPSC
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FIGURE 5 | Continued
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FIGURE 5 | Continued
(A) Immature neuronal cells that were cultured in a Dopaminergic Neuronal
Progenitor Medium began to show morphological signs of neuronal
maturity between Day 29–50 (a,b,c) and after 6 months these cells
displayed further signs of mature network formation (d). Importantly, control
tail cells that were not subject to the reprogramming procedures kept their
original shape at 6 months (e). As well, during this time, expression of the
early immature neuronal cell marker, DCX, was greatly diminished (f),
together with increased expression of the mature general neuronal cell
marker, microtubule associated protein 2 (MAP2), (g), and speciﬁc
dopaminergic neuronal marker, tyrosine hydroxylase (TH), (h) was evident.
Further conﬁrmation that the reprogrammed neurons were mature
dopaminergic neurons was obtained using HPLC (i); wherein tail cells that
were re-programmed (Tail-Dopamine cells) displayed signiﬁcantly increased
dopamine levels, compared to non-reprogrammed controls (Tail cells).
Furthermore, dopamine levels in non-reprogrammed controls were, as
expected, quite low (Tail tissue), whereas freshly dissected adult midbrain
tissue had the expected highest concentration of dopamine (Brain tissue).
*p < 0.05, relative to control tails. (B) Shows the time course for
dopaminergic neuron derivation. The adult mouse (aged 2 months)
ﬁbroblasts were reprogrammed by vector 20866 with c-Myc, Klf4, Oct4,
and Sox2 genes and an mOrange marker was used to detect gene
expression after 2-weeks in cell culture (a). Induced pluripotent stem cells
(iPSCs) began to show obvious outgrowths at Days 15 and 20 (b). The
undifferentiated iPSCs were transformed into neural progenitor cells
following culture in the Neural Induction Medium (see Materials and
Methods) during Days 21–28 (c). The neural progenitor cells were further
differentiated into dopaminergic neural progenitors with the Dopamine
Neuronal Progenitor Medium from Days 29–35 (d). From Days 36 to 50, the
cells were subsequently differentiated into mature dopaminergic neurons
by culturing in the Dopamine Neuronal Differentiation Medium (e,f,g). The
mature dopaminergic neurons were grown for up to 6 months (h), and were
visibly easy to distinguish from the original un-reprogrammed adult
ﬁbroblasts from parallel control cultures (i).
lines. Speciﬁcally, neural progenitor cells were ﬁrst produced from
reprogrammed adult mouse tail-tip cells using a neuronal pro-
genitor medium during Days 29–35 (Figure 5A-a). Then, from
Day 36 to 50, these cells were further directed to differentiate
into midbrain mature dopaminergic neurons using a dopamine
neuronal differentiation medium (see Materials and Methods). At
this point, the cells showed clear signs of forming mature neu-
ral networks (Figure 5A-b,c). Importantly, long-term observation
of these cell lines until 6 months after the initial ﬁbroblast cell
reprogramming revealed that the cultured dopaminergic neu-
rons still had a pronounced ability to form mature neuronal
networks (Figure 5A-d). In contrast, at the 6-month mark,
tail-tip ﬁbroblast cells grown in control cultures (i.e., without
cell reprogramming and differentiating media) maintained their
original shape and failed to form any visible cellular networks
(Figure 5A-e).
These signiﬁcant developmental changes were characterized by
greatly diminished expression of the early neuronal marker, DCX
(Figure 5A-f), along with enhanced expression of the mature neu-
ronal marker, MAP2 (Figure 5A-g). As well, these in vitro gener-
ated neurons expressed TH, the rate-limiting enzyme in dopamine
synthesis (Figure 5A-h). Further evidence for a dopaminergic phe-
notype of the re-programmed neurons is evident from the ability
of these cells to actually produce dopamine (Figure 5A-i). Indeed,
concentrations of dopaminewere increased in the re-programmed
tail cells (364 pg/mg protein) compared to the original non-
re-programmed tail tissue (169 pg/mg protein). The dopamine
levels of the re-programmed cells approached those evident
in actual dissected adult midbrain tissue (486 pg/mg protein).
Together, these data are strongly indicative of a dopaminergic cell
phenotype.
As a summary, Figure 5B presents the time course for the
reprogramming of ﬁbroblasts through progressive stages includ-
ing clustered iPSCs (Figure 5B-a), followed by cellular out-
growths (Figure 5B-b), differentiation into neural progenitor cells
(Figure 5B-c), dopaminergic neural progenitors (Figure 5B-d)
and ﬁnally mature dopaminergic neurons (Figure 5B-e,f,g,h). The
cellular morphology and series of network connections were eas-
ily visible and distinguishable from the original un-reprogrammed
adult ﬁbroblasts from parallel control cultures (Figure 5B-i).
iPSC-DERIVED MATURE DOPAMINERGIC NEURONS SURVIVE
FOLLOWING TRANSPLANTATION
To evaluate neuronal survival and viability, TH and BDNF mRNA
were determined in the cortex (Figures 6A,C) and hippocampus
(Figures 6B,D). As predicted, in both brain regions BDNF mRNA
was increased most robustly in mice transplanted with the BDNF-
transfected neurons (red lines). Relative to controls (HBSS vehicle
alone; blues lines), mice infused with mature dopaminergic neu-
rons only (i.e., in the absence of BDNF; green lines) displayed
intermediate elevations of TH mRNA and BDNF mRNA. These
data suggest that the ﬁbroblast-derivedmature dopaminergic neu-
rons can survive for at least for 24-h in mouse brain in vivo, during
which time they appear to be capable of up-regulating TH and
BDNF expression.
We ﬁrst provide evidence that infused cells that had cDNA
BDNF were actually still viable at 2 weeks following their central
infusion (Figure 7). Speciﬁcally, slides were imaged for the vec-
tor 20866 biomarker using mOrange, and ZsYellow1 for BDNF.
Clearly, a positive signal was observed for both ﬂuorescent chan-
nels and the signals were highly co-localized, suggesting that the
infused cells (at least a subset) still survived after 2 weeks in vivo.
As shown in Figure 7, cellular bodies (upper panels) and ﬁbers
(lower panels) were apparent from the infused cells.
DISCUSSION
The recently developed iPSC-generating technologies allow for the
transplantation of stem cells (or even mature neurons) derived
from one’s own somatic cells. This could conceivably pave the
way for the advent of patient- and disease-speciﬁc stem cell treat-
ments (i.e., for personalized medicine). Although most current
iPSC-generating systems are virus-based, the feasibility of gen-
erating iPSCs from ﬁbroblasts using a single excisable non-viral
vector containing a 4-gene reprogramming cassette is beginning
to be assessed. In the present investigation we have taken the
“next step” by demonstrating that iPSC-derived cells transformed
into neural cells had functional consequences in the context of
stressor exposure, and that some of these effects were further
modiﬁed when the iPSC-derived cells were engineered to express
BDNF.
In the present investigation we were particularly interested in
using iPSC-derived cells as a means of stably delivering BDNF
into the brain and assessing whether this would elicit “anti-
stress” effects that could be beneﬁcial for modulating stressor-
induced pathology. Indeed, intracerebroventricular infusion of
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FIGURE 6 | Survival of iPSC-derived mature dopaminergic neurons in
vivo. Transplanted (i.e., intracerebroventricular infusion) neurons of an
apparent dopaminergic phenotype (re-programmed tail cells after 50 days
in differentiation medium) displayed clear elevations of TH and BDNF
expression after 24 h. Panels (A,B) display TH mRNA, while (C,D) display
BDNF mRNA within cortical and hippocampal dissected tissue. Within
each of the four panels, identical patterns of gene expression were
observed. Namely, the dopaminergic neurons (previously reprogrammed
by vector 20866) plus transfected cDNA BDNF (red lines) induced the
highest level of TH and BDNF expression, whereas dopaminergic neurons
(previously reprogrammed by vector 20866) in the absence of BDNF
cDNA had intermediate levels of expression (green lines) and the HBSS
controls clearly had the as the lowest (background) gene expression (blue
lines).
FIGURE 7 |The reprogrammed cells were directly imaged to observe
the mOrange, which was linked to the 20866 vector, and ZsYellow1,
which was linked to the cDNA BDNF. Both ﬂuorescent channels showed
positive signals for the reprogramming vector (mOrange) and BDNF
(ZsYellow) and these were highly co-localized (merge). Mice that received
the non-reprogrammed control cells failed to display and positive cellular
ﬂuorescent staining and are hence, not shown. However, the upper (A) and
lower (B) photomicrographs depict images of positive soma and ﬁber
projections, respectively, from the vector 20866 + BDNF cDNA infused
animals. Importantly, the speciﬁc genes were within the same reading
frame and images were collected immediately adjacent to the site of
infusion.
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iPSC-derived neural progenitors (i.e., DCX expressing immature
neurons) did blunt the impact of LPS + chronic stressor exposure
upon neurogenesis and corticosterone levels, two key mediators of
stressor related pathology (Tanti and Belzung, 2013). Moreover, in
addition to the neural progenitor cells, wewere able to create iPSC-
derived mature dopamine producing neurons that survived, at
least transiently, following in vivo infusion. However, it remains to
be determined if these more mature neurons can usefully integrate
into endogenous neural circuits and impart long-term functional
changes.
Stressor exposure has been strongly linked to the develop-
ment of psychiatric conditions (Golden et al., 2011), and immune
challenges were shown to further augment the impact of stres-
sors (Gibb et al., 2011; Hayley, 2011). Moreover, in the case of
major depression, structural and functional changes have been
documented in discrete brain regions, including the hippocam-
pus and amygdala (van Eijndhoven et al., 2009; Sheline et al.,
2012; Bielau et al., 2013; Vassilopoulou et al., 2013). Yet, there
are no known clinically available treatments that speciﬁc tar-
get such potential neuronal or synaptic pathology, rather than
simply managing neurotransmitter disturbances. Intriguingly
however, one preclinical study reported that intracerebroven-
tricularly infused mesenchymal stem cells migrated to the hip-
pocampus and promoted antidepressant-like behavioral effects,
along with increased neurogenesis in adult rodents (Tﬁlin et al.,
2010).
Curiously, in the present investigation central infusion of iPSC-
derived neural cells did not affect hippocampal neurogenesis,
although it did reverse the LPS + stressor-induced reduction
of SVZ neurogenesis. It is likely that the SVZ region was selec-
tively affected given its proximity to the site of infusion. Most
importantly, BDNF appeared to be a key factor in promot-
ing SVZ neurogenesis, as infusion of the iPSC derived cells in
the absence of enhanced BDNF expression had no signiﬁcant
effect. As well, the fact that infusion of iPSC derived cells mod-
estly blunted (∼30%) the corticosterone elevation induced by
LPS + stressor exposure is tantalizing and raises the possibility
that the infused cells may have been inﬂuencing hippocampal
or conceivably even hypothalamic neurons, thereby modulat-
ing their respective inhibitory or excitatory control of CRH
neuronal activity. Of course, another possibility that warrants
consideration is that the infused iPSC derived cells induced
non-speciﬁc compensatory responses that serve to keep stres-
sor reactivity in check, or that the exogenous cells might have
inﬂuenced processes aligned with habituation to the ongoing
stressor.
Taken together, the current ﬁndings represent a starting point
for future studies aimed at the possibility of combining stem
cells (as a cell replacement therapy and gene delivery tool) and
BDNF (as a trophic factor) as a potential strategy for dealing
with stressor or immune challenge induced neuronal pathol-
ogy. In particular, long-term stable BDNF expression in specially
tailored neuron cells could potentially stimulate neurogenesis
and repair, contribute to neuroprotection and possibly modu-
late the impact of psychological stressors (Greisen et al., 2005;
Nomura et al., 2005; Anisman et al., 2008; Hayley, 2011). We
urge caution in interpreting these data as we are uncertain as
to whether the exogenously administered iPSC derived cells:
(1) actually integrated into the existing neural circuitry or (2)
induced endogenous factor(s), which in turn affected the out-
comes, including HPA and neurogenic responses. Indeed, further
studies are required to verify whether the infused cells were the sole
source of increased central BDNF and if iPSC-derived cells could
permanently inﬂuenceneural circuitry. That said, the present tech-
nical approach is novel and deserves further study concerning its
potential applicability for a variety of animal models of disease.
Ultimately, it is hoped that future work can identify the condi-
tions that favor beneﬁcial additive or even synergistic outcomes
with the over-expression of trophic factors in iPSC-derived neural
cells.
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